248
Participants
Start Date
April 27, 2016
Primary Completion Date
October 18, 2019
Study Completion Date
August 15, 2022
Panobinostat Capsules
20 mg, 10 mg or 15 mg (for dose reductions only)
Bortezomib Injection
1.3 mg/square meter subcutaneous administration. Cycle 1-4: 2 weeks on/1 week off, BIW for participants ≤ 75 years at time of screening; once a week for participants \> 75 years. Cycle 5+: once a week for all participants.
Dexamethasone tablets
Pre and 24 hours after bortezomib administration. Participants ≤ 75 years at time of screening: 20 mg/dose participants; \> 75 years: 10 mg/dose.
Novartis Investigative Site, Sidon
Novartis Investigative Site, Budapest
Novartis Investigative Site, Prahran
Novartis Investigative Site, Hasselt
Novartis Investigative Site, Debrecen
Novartis Investigative Site, Nyíregyháza
Novartis Investigative Site, Kaposvár
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Lake Success
Novartis Investigative Site, Prague
Novartis Investigative Site, Bad Saarow
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Kiel
Novartis Investigative Site, Morgantown
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Málaga
Novartis Investigative Site, Atlanta
Novartis Investigative Site, Gainesville
Novartis Investigative Site, Pessac
Novartis Investigative Site, Istanbul
Novartis Investigative Site, Izmir
Novartis Investigative Site, Salamanca
Novartis Investigative Site, Grenoble
Novartis Investigative Site, San Cristóbal de La Laguna
Novartis Investigative Site, Nonthaburi
Novartis Investigative Site, Louisville
Novartis Investigative Site, Nantes
Novartis Investigative Site, Rimini
Novartis Investigative Site, Zaragoza
Novartis Investigative Site, Chiang Mai
Novartis Investigative Site, Metz
Novartis Investigative Site, Hwasun
Novartis Investigative Site, Lille
Novartis Investigative Site, Bayonne
Novartis Investigative Site, Darmstadt
Novartis Investigative Site, Fayetteville
Novartis Investigative Site, Paris
Novartis Investigative Site, Fort Collins
Novartis Investigative Site, Avignon
Novartis Investigative Site, La Roche-sur-Yon
Novartis Investigative Site, Los Angeles
Novartis Investigative Site, Bayreuth
Novartis Investigative Site, Beirut
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Saratov
Novartis Investigative Site, Braga
Novartis Investigative Site, Boston
Novartis Investigative Site, Barretos
Novartis Investigative Site, São Paulo
Novartis Investigative Site, São Paulo
Novartis Investigative Site, Edmonton
Novartis Investigative Site, Kitchener
Novartis Investigative Site, Ostrava Poruba
Novartis Investigative Site, Dresden
Novartis Investigative Site, Halle
Novartis Investigative Site, Leipzig
Novartis Investigative Site, Athens
Novartis Investigative Site, Athens
Novartis Investigative Site, Pátrai
Novartis Investigative Site, Roma
Novartis Investigative Site, Beirut
VUmc, Hematology, PK2 BR012, Amsterdam
Albert Schweitzer ziekenhuis, Hematology, Dordrecht
Novartis Investigative Site, Oslo
Novartis Investigative Site, Lublin
Novartis Investigative Site, Torun
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Wroclaw
Novartis Investigative Site, Porto
Novartis Investigative Site, Seoul
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Barcelona
Novartis Investigative Site, L'Hospitalet de Llobregat
Novartis Investigative Site, Luleå
Novartis Investigative Site, Lund
Novartis Investigative Site, Uppsala
Novartis Investigative Site, Ankara
pharmaand GmbH
INDUSTRY